Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers with androgenetic alopecia

Next Previous
Trial Profile

A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers with androgenetic alopecia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FOL 005 (Primary)
  • Indications Alopecia
  • Focus Therapeutic Use
  • Sponsors Follicum AB

Most Recent Events

  • 15 Sep 2021 According to a Follicum AB media release, following the spring results from this phase 2 study of FOL-005 in the treatment of hair loss, the board decided to evaluate the company's business strategy and long-term goals.
  • 03 Jun 2021 According to a Follicum AB media release, It is currently not possible to assess whether the new analysis will result in any reassessment of the conclusions previously drawn on the drug candidates effect on hair loss. Follicum will return as soon as possible with the results of the re-analysis.
  • 03 Jun 2021 According to a Follicum AB media release, the contract research organization (CRO) together with Follicum, has discovered possible inaccuracies in the results analysis of this trial . Follicum has hired an independent reviewer who will now review all study data and assess the extent to which this affects the recently reported results.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top